ASCO GU 2023 - Results from #100

Viewing 101-120 of 190 articles

ASCO GU 2023: Cell-Free Urinary Tumor DNA to Detect Minimal Residual Disease Prior to Repeat-Transurethral Resection of Bladder Tumor in Non–muscle-Invasive Bladder Cancer: A Prospective Study

ASCO GU 2023: Intravesical Gemcitabine and Docetaxel in the Treatment of BCG-Naïve Non–muscle Invasive Urothelial Carcinoma of the Bladder: Updates from a Phase 2 Trial

ASCO GU 2023: Quality of Life in QUILT 3.032 Study: Patients with BCG-Unresponsive NMIBC Receiving IL-15RαFc Superagonist N-803 plus BCG

ASCO GU 2023: A Phase 2 Basket Study of Tucatinib and Trastuzumab in Previously Treated Solid Tumors with HER2 Alterations: Urothelial Cancer Cohort (SGNTUC-019)

ASCO GU 2023: Complimentary Genomic, Pathologic, and Artificial Intelligence Analysis on Low-Grade Noninvasive Bladder Cancer to Predict Downstream Recurrence

ASCO GU 2023: The Impact of F-18 PSMA PET Imaging on Clinical Decision-Making in Prostate Cancer Across Disease States

ASCO GU 2023: Patterns of Failure with 18F-DCFPyL PSMA PET/CT in the Post-Prostatectomy Setting: A Regional Cohort Analysis

ASCO GU 2023: NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)

ASCO GU 2023: Impact of 68Ga-PSMA PET/CT in Patients with mCRPC Treated with Enzalutamide

ASCO GU 2023: Effect of Body Weight on Standardized Uptake Values on 18F-DCFPyL PSMA PET/CT in Patients with Prostate Cancer

ASCO GU 2023: Niraparib with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Gene Alterations: Second Interim Analysis of MAGNITUDE

ASCO GU 2023: Clinical Implementation of 177Lu-PSMA-617 at a Major Academic Center: Initial Experiences

ASCO GU 2023: Developing a Novel Patient-Reported Outcome Measure for Patients with Prostate Cancer Receiving Radionuclide Therapy: The FACT-RNT

ASCO GU 2023: AlphaBet: A Phase I/II Trial Evaluating the Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in Patients with mCRPC

ASCO GU 2023: First-in-Class Oral Innate Immune Activator BXCL701 Combined with Pembrolizumab in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC) of Small Cell Neuroendocrine (SCNC) Phenotype: Phase 2a Final Results

ASCO GU 2023: Randomized, Double-Blinded Phase II Study of Ketoconazole, Hydrocortisone, and Anti-PSMA Antibody J591 Labeled with 177Lu or 111In in Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0 CRPC)

ASCO GU 2023: A Phase I/II Dose-Escalation Study of Fractionated 225Ac-J591 for Progressive mCRPC in Patients with Prior Treatment with 177Lu-PSMA

ASCO GU 2023: 68GaPSMA-11 PET/CT to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and PSMA Response

ASCO GU 2023: Dosing, Safety, and Pharmacokinetics of Combination Therapy with Darolutamide, ADT, and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in the ARASENS Study

ASCO GU 2023: Detection of True Positive M1 Lesions by 18F-rhPSMA-7.3 PET in Newly Diagnosed Prostate Cancer: Results from the Phase 3 Prospective LIGHTHOUSE Study

1
2
3
4
5
6
7
8
9
10